New hope for tough blood cancers: first human trial of GLB-001 begins

NCT ID NCT06146257

Recruiting now Disease control Sponsor: GluBio Therapeutics Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests an experimental oral drug called GLB-001 in adults whose acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes (MDS) have come back or not responded to treatment. The study aims to find a safe dose and see if the drug shows any signs of working. About 48 participants will be enrolled in two parts: dose escalation and dose expansion.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GLB-001 (an oral drug)
What this could lead to: If successful, this could lead to a new oral treatment option for people with hard-to-treat AML or MDS.
What could go wrong: This is a very early Phase 1 trial with only 48 participants, so safety and effectiveness are not yet known. Many drugs fail at this stage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia myelodysplastic syndrome Myelodysplastic Syndromes

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA MYELODYSPLASTIC SYNDROMES

Contacts and locations

Locations

Alliance for Multispecialty Research, LLC
TERMINATED

Merriam, Kansas, 66204, United States
City of Hope Medical Center
RECRUITING

Duarte, California, 91010, United States
Icahn School of Medicine at Mount Sinai
RECRUITING

New York, New York, 10029, United States
Memorial Sloan Kettering Cancer Center-David H. Koch Center
TERMINATED

New York, New York, 10021, United States
Roswell Park Comprehensive Cancer Center
TERMINATED

Buffalo, New York, 14263, United States
University of California Irvine
TERMINATED

Irvine, California, 92697, United States
University of Kansas Medical Center Research Institute, Inc.
RECRUITING

Kansas City, Kansas, 66160, United States
University of Texas M. D. Anderson Cancer Center
TERMINATED

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.